Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021

ACR Convergence 2022

Summaries from ACR Convergence 2022, held from November 10 – 14, 2022.

Guselkumab sustains improvements in work productivity and daily activity in patients with active psoriatic arthritis

Presenter: Jeffrey Curtis, MD, University of Alabama at Birmingham, Birmingham, AL

Guselkumab-treated patients with psoriatic arthritis show sustained improvements in work productivity and daily activity through 2 years.

Short composite measures identify disease activity in psoriatic arthritis

Presenter: William Tillett, PhD, MBChB, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

Abbreviated visual analogue scales can accurately assess disease activity in psoriatic arthritis.

Guselkumab provides consistent long-term efficacy in psoriatic arthritis

Presenter: Iain McInnes, PhD, FRCP, University of Glasgow, Glasgow, United Kingdom

Guselkumab significantly improves the signs and symptoms of psoriatic arthritis across all baseline patient subgroups, including those with highly active disease, regardless of the dosing regimen for up to 2 years.

Peripheral blood methylation may become useful biomarker in knee osteoarthritis

Presenter: Matlock Jeffries, MD, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States

An analysis of peripheral blood epigenetic patterns may predict which patients with knee osteoarthritis are likely to progress.

Risk assessment score guides screening of systemic sclerosis-associated interstitial lung disease

Presenter: Cosimo Bruni, MD, PhD, University of Florence, Florence, Italy

Researchers develop a risk assessment scoring system to guide the use of high-resolution computed tomography to detect interstitial lung disease in patients diagnosed with systemic sclerosis.

Guselkumab improves psoriatic arthritis disease activity in multiple composite scores

Presenter: Laure Gossec, MD, PhD, Sorbonne Universite, Paris, France

Guselkumab provides substantial improvement in disease activity across multiple composite scores for patients with active psoriatic arthritis (PsA) who were refractory to tumor necrosis factor (TNF) inhibitor therapy.

Guselkumab enhances responses in patients with psoriatic arthritis and active axial involvement

Presenter: Philip Mease, MD, Swedish Medical Center/Providence-St Joseph Health, Seattle, WA

Patients with psoriatic arthritis and active axial involvement treated with guselkumab show significant and clinically meaningful improvements in disease activity after 2 years.

Combination therapy with an NSAID and TNF inhibitor only slightly slows spinal progression of radiographic axial spondyloarthritis

Presenter: Fabian Proft, MD, Department of Gastroenterology, Infectious Disease and Rheumatology, Charité — Universitätsmedizin Berlin, Berlin, Germany

This study found no significant benefit from combined treatment with an NSAID and a TNF-inhibitor in reducing spinal progression in patients with radiographic axial spondyloarthritis; however, this therapy may have efficacy in some high-risk patients.

Pegloticase plus methotrexate increases response rates in uncontrolled gout cases

Presenter: John Botson, MD, Orthopedic Physicians Alaska, Anchorage, AK

A combination of pegloticase and methotrexate continues to sustain high rates of urate-lowering response in patients with uncontrolled gout at 12 months

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire